GlassScriptPhysician profile
Michael A Dundr
NPI 1972711851
$2,143.17
in general payments reported to CMS, 2019-2025
36 companies · $112 in 2025
The $112 reported for 2025 was more than what a typical General Practice provider received nationally (typical 2025 total: $105).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $437 · 2020: $171 · 2021: $73.10 · 2022: $138 · 2023: $722 · 2024: $490 · 2025: $112.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,324.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,323.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $423.91 | 2021-2024 | Vraylar, Linzess, Viberzi |
| Pfizer INC. | $256.87 | 2019-2024 | |
| Astrazeneca Pharmaceuticals LP | $199.64 | 2019-2024 | Farxiga, Airsupra |
| Exact Sciences Corporation | $122.79 | 2023-2024 | Cologuard Collection Kit |
| Glaxosmithkline, LLC. | $84.79 | 2019-2023 | Trelegy Ellipta |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $80.01 | 2019-2023 | Xifaxan |
| Novo Nordisk INC | $75.32 | 2019-2024 | Rybelsus, Ozempic |
| Boehringer Ingelheim Pharmaceuticals, INC. | $70.03 | 2020-2025 | Jardiance |
| Novartis Pharmaceuticals Corporation | $57.63 | 2019-2024 | |
| Amgen INC. | $54.79 | 2019-2021 | |
| Amarin Pharma, INC. | $52.27 | 2019-2020 | |
| Otsuka America Pharmaceutical, INC. | $50.63 | 2023 | Rexulti |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $44.19 | 2023-2024 | Caplyta |
| Boston Scientific Corporation | $42.73 | 2025 | Cds - Mct/Cem Monitoring |
| Sanofi-Aventis U.S. LLC | $40.29 | 2019-2023 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $38.07 | 2019-2020 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $36.49 | 2024-2025 | Lifevest |
| Corcept Therapeutics | $35.07 | 2024-2025 | Korlym |
| Merck Sharp & Dohme LLC | $34.88 | 2021 | |
| Aimmune Therapeutics, INC. | $31.24 | 2024 | |
| Allergan, INC. | $29.99 | 2020 | |
| Phathom Pharmaceuticals, INC. | $28.01 | 2023-2024 | Voquezna |
| E.R. Squibb & Sons, L.L.C. | $27.71 | 2019 | |
| Biohaven Pharmaceutical Holding Company LTD. | $27.41 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $27.16 | 2019-2024 | Austedo Xr |
| Avanir Pharmaceuticals, INC. | $22.58 | 2019-2020 | |
| Dexcom, INC. | $18.46 | 2024 | Dexcom G6 Transmitter |
| Sumitomo Pharma America, INC. | $17.15 | 2024 | Gemtesa |
| Axsome Therapeutics, INC. | $16.91 | 2023 | Auvelity |
| Neurocrine Biosciences, INC. | $16.89 | 2025 | |
| Urovant Sciences INC | $16.69 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $14.21 | 2024 | |
| Horizon Therapeutics Plc | $13.15 | 2022 | |
| Xeris Pharmaceuticals, INC. | $12.53 | 2022 | |
| Gilead Sciences, INC. | $11.69 | 2019 | |
| Currax Pharmaceuticals LLC | $10.99 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Dundr listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.